Bristol, United Kingdom – Scarlet Therapeutics Ltd, a pioneering biotechnology research company, announced today the successful completion of its seed funding round. The investment was led by Science Creates Ventures, a renowned venture capital firm specializing in supporting groundbreaking scientific advancements. This funding milestone will enable Scarlet Therapeutics to accelerate the development of its unique platform, focused on generating novel red blood cell-based therapeutics for the treatment of various diseases.

Scarlet Therapeutics is at the forefront of revolutionizing therapeutic approaches with its proprietary technology. Leveraging more than a decade of groundbreaking research conducted at the University of Bristol, the company has developed a platform that harnesses the potential of therapeutic red blood cells (tRBCs). These tRBCs exhibit exceptional characteristics, including extensive systemic distribution, prolonged lifespan, and the ability to encapsulate and protect active proteins from the immune system.

Ash Toye, Co-Founder of Scarlet Therapeutics, expressed excitement about the company's future prospects, stating, "This seed funding marks a significant milestone in our journey to revolutionize the field of therapeutics. With the support of Science Creates Ventures, we are well-positioned to unlock the full potential of our red blood cell-based platform technology. Scarlet Therapeutics is committed to pushing the boundaries of scientific innovation and transforming the lives of patients suffering from a wide range of diseases."